biotech한국경제 IT (Hankyung)· 7/29/2026, 1:03:20 AM★ 8.0
Kangstem Biotech's Osteoarthritis Treatment Demonstrates Efficacy in Phase 2a Trial
Kangstem Biotech's osteoarthritis treatment candidate OSCA showed statistically significant improvements in pain and joint function metrics, as well as structural cartilage changes detected via MRI, in its phase 2a trial. The company reported 24-week results showing significant differences between the test group and placebo group across multiple outcome measures, including VAS, IKDC, WOMAC, and KOOS scores, with no safety concerns noted.
💡 AI analysis: The Phase 2a success of OSCA validates the efficacy of stem cell-based osteoarthritis therapy, signaling a major milestone for Kangstem Biotech's potential global licensing or commercialization.